Decreased plasma membrane expression of striatal dopamine transporter in aging

Neurobiology of Aging

Volumn 24, Issue 8, 2003, Pages 1147-1154

  Salvatore, Michael F ^a   Apparsundaram, Subbu ^a   Gerhardt, Greg A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Aging; Dopamine transporter; Mesolimbic; Nigrostriatal; Nucleus accumbens; Striatum; Tyrosine hydroxylase

Indexed keywords

BIOTIN DERIVATIVE; BRAIN PROTEIN; CARRIER PROTEIN; DOPAMINE; DOPAMINE BINDING PROTEIN; DOPAMINE TRANSPORTER; DOPAMINE-BINDING PROTEIN; TRITIUM; TYROSINE 3 MONOOXYGENASE;

AGE; AGING; ANIMAL; ANIMAL TISSUE; BINDING SITE; BIOTINYLATION; BRAIN LEVEL; BRAIN REGION; BRAIN SYNAPTOSOME; CELL MEMBRANE; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ENZYME ASSAY; GROUPS BY AGE; IMMUNOREACTIVITY; LIGAND BINDING; MALE; METABOLISM; NEOSTRIATUM; NERVE CELL MEMBRANE; NERVE TRACT; NEUROPIL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RADIOASSAY; RAT; RAT STRAIN; SUBSTANTIA NIGRA; SYNAPTOSOME; TISSUE DISTRIBUTION; VENTRAL TEGMENTUM; WESTERN BLOTTING;

EID: 0344413549     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00129-5     Document Type: Conference Paper

References (41)

1. 3H ] GBR-12935 in human putamen Neurobiol. Aging. 10:1989;661-664.
2. Apparsundaram S., Schroeter S., Giovanetti E., Blakely R.D. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. J. Pharmacol. Exp. Ther. 287:1998;744-751.
3. Bannon M.J., Poosch M.S., Xia Y., Goebel D.J., Cassin B., Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7095-7099.
4. Bannon M.J., Whitty C.J. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology. 48:1997;969-977.
5. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M.et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N. Engl. J. Med. 334:1996;71-76.
6. Blakely R.D., Bauman A.L. Biogenic amine transporters: regulation in flux. Curr. Opin. Neurobiol. 10:2000;328-336.
7. 2+-dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum. J. Neurosci. 21:2001;7841-7847.
8. Daniels G., Amara S.G. Regulated trafficking of the human dopamine transporter: clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274:1999;35794-35801.
9. Doolen S., Zahniser N.R. Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes. J. Pharmacol. Exp. Ther. 296:2001;931-938.
10. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D.et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401:1998;253-265.
11. Friedemann M.N., Gerhardt G.A. Regional effects of aging on dopaminergic function in the Fischer-344 rat. Neurobiol. Aging. 13:1992;325-332.
12. Gainetdinov R.R., Caron M.G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 43:2003;261-284.
13. Gerhardt G.A., Cass W.A., Henson M., Zhang Z., Ovadia A., Hoffer B.J.et al. Age-related changes in potassium-evoked overflow of dopamine in the striatum of the rhesus monkey. Neurobiol. Aging. 16:1995;939-946.
14. Gerhardt G.A., Maloney R.E. Microdialysis studies of basal levels and stimulus-evoked overflow of dopamine and metabolites in the striatum of young and aged Fischer 344 rats. Brain Res. 816:1999;68-77.
15. Gerhardt G.A., Cass W.A., Yi A., Zhang Z., Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged Rhesus monkeys. J. Neurochem. 80:2002;168-177.
16. Gulley J.M., Doolen S., Zahniser N.R. Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J. Neurochem. 83:2002;400-411.
17. Haycock J.W. Quantitation of tyrosine hydroxylase protein levels: spot immunolabeling with an affinity purified antibody. Anal. Biochem. 181:1989;259-266.
18. Hebert M.A., Gerhardt G.A. Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in Fischer 344 rats. Brain Res. 797:1998;42-54.
19. Hebert M.A., Gerhardt G.A. Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study. J. Pharmacol. Exp. Ther. 288:1999;879-887.
20. 3H ] WIN 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the Fischer 344 rat J. Pharmacol. Exp. Ther. 288:1999;1334-1339.
21. Hoffman A.F., Gerhardt G.A. Differences in pharmacological properties of dopamine release between the substantia nigra and striatum: an in vivo electrochemical study. J. Pharmacol. Exp. Ther. 289:1999;455-463.
22. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
23. Kish S.J., Zhong X.H., Hornykiewicz O., Haycock J.W. Striatal 3,4-dihydroxyphenyalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies. Ann. Neurol. 38:1995;260-264.
24. Kubis N., Faucheux M.A., Ransmayr G., Damier P., Duyckaerts C., Henin D.et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain. 123:2000;366-373.
25. Letchworth S.R., Sexton T., Childers S.R., Vrana K.E., Vaughan R.A., Davies H.M.et al. Regulation of rat dopamine transporter mRNA and protein by chronic cocaine administration. J. Neurochem. 73:1999;1982-1989.
26. Little K.Y., Elmer L.W., Zhong H., Scheys J.O., Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 61:2002;436-445.
27. Ma S.Y., Ciliax B.J., Stebbins G., Jaffar S., Joyce J.N., Cochran E.J.et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J. Comp. Neurol. 409:1999;25-37.
28. Melikian H.E., Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19:1999;7699-7710.
29. Melikian H.E., Ramamoorthy S., Tate C.G., Blakely R.D. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol. Pharmacol. 50:1996;266-276.
30. Mozley P.D., Acton P.D., Barraclogh E.D., Plossl K., Gur R.C., Alavi A. et al. Effects of age on dopamine transporters in healthy humans. J. Nucl. Med. 40:1999;1812-1817.
31. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16:1996;436-447.
32. Pristupa Z.B., McConkey F., Liu F., Man H.Y., Lee F.J., Wang Y.T.et al. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse. 30:1998;79-87.
33. Reszka A.A., Seger R., Diltz C.D., Krebs E.G., Fischer E.H. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8881-8885.
34. Salvatore M.F., Garcia-Espana A., Goldstein M., Deutch A.Y., Haycock J.W. Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo: effects of acute haloperidol and related compounds. J. Neurochem. 75:2000;225-232.
35. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D.et al. Measurement of protein using bichinchoninic acid. Anal. Biochem. 150:1985;76-85.
36. Stanford JA, Hebert ME, Gerhardt GA. Biochemical and anatomical changes in basal ganglia of aging animals. In: Hof PR, Mobbs CV, editors. Functional neurobiology of aging. New York: Academic Press; 2001. p. 727-36.
37. Taubenblatt P., Dedieu J.C., Gulik-Krzywicki T., Morel N. VAMP (synaptobrevin) is present in the plasma membrane of nerve terminals. J. Cell Sci. 112:1999;3559-3567.
38. Vaughan R.A., Huff R.A., Uhl G.R., Kuhar M.J. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J. Biol. Chem. 272:1997;15541-15546.
39. Volkow N.D., Wang G.J., Fowler J.S., Ding Y.S., Gur R.C., Gatley J.et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann. Neurol. 44:1998;143-147.
40. Wolf M.E., LeWitt P.A., Bannon M.J., Dragovic L.J., Kapatos G. Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate. J. Neurochem. 56:1991;1191-1200.
41. - dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol. Ther. 92:2001;21-55.